Biovision Biomedical Technology key facts
- Operator of a clinical-stage biopharmaceutical company intended to focus on the discovery, development, and commercialization of novel targeted radiopharmaceuticals to address significant unmet…
- It has raised $42.3M; the latest was Early Stage VC ($13.7M) in Jan 2025.
- Notable investors include CICC Capital, Yijing Capital, VI Ventures, Elikon Venture, Gaorong Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch Biovision Biomedical Technology: the Monday email on marks, rounds and moves
Biovision Biomedical Technology funding rounds
No funding rounds for Biovision Biomedical Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Biovision Biomedical Technology investors
10 investors are on record for Biovision Biomedical Technology, including CICC Capital, Yijing Capital, VI Ventures and Elikon Venture.
About Biovision Biomedical Technology
Operator of a clinical-stage biopharmaceutical company intended to focus on the discovery, development, and commercialization of novel targeted radiopharmaceuticals to address significant unmet medical needs. The company's proprietary technology platform for selecting targeting ligands, radiation drug-conjugate, and translational medicine for its drug R&D programs, enabling patients with advanced treatments.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 25
- Website
- bivisionpharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Biovision Biomedical Technology doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.